比較含等量植物雌激素之單一藥材和中藥方劑對停經後骨質疏鬆症之預防-中藥方劑內成分間是否有加強作用之研究

楊育正主任 
馬偕紀念醫
在我們之前的研究已分析過不同之中藥材之植物雌激素含量。本計劃則針對下列三組停經後婦女進行研究。第一組給予富含植物雌激素之單一中藥，其植物雌激素之含量和第二組相等，第二組給予中藥方劑(壯骨二號)，第三組給予標準之賀爾蒙補充療法。三組皆給予鈣質補充。

尿液及血中之植物雌激素濃度、生化標記(包括血清骨特異性鹼性磷酸脢及尿液中NTX)於收案時及每三個月檢測一次，骨密度及子宮內膜厚度則於收案時及追蹤一年後各測量一次，所有病人皆治療及追蹤至少一年。

我們預期獲得下列結果1.治療前之骨密度值與其基礎植物雌激素濃度成正相關。2.中藥之投與有助於預防骨質疏鬆症。3.中藥對於骨質密度之作用與標準賀爾蒙補充療法相當。4.中藥方劑由於配方之加強作用，比含等量植物雌激素之單一中藥更能有效預防骨質疏鬆症。

關鍵字：植物雌激素，中藥方劑，停經後骨質疏鬆症

Comparison of equivalent phytoestrogens in single herb and herbal regimen on prevention of postmenopausal osteoporosis – Is there synergistic effect in components of herbal regimen ?

Yuh-Cheng Yang
Mackay Memorial Hospital
We have previously analyzed the phytoestrogen content in different herbs used in Chinese medicine. This study is designed to compare 3 groups of patients, group 1, postmenopausal women treated with phytoestrogen-containing herb; group 2, postmenopausal women treated with herbal regimen containing equivalent phytoestrogen as in group 1; group 3, postmenopausal women treated with standard HRT. Calcium supplementation will be given to all 3 groups. 

The urinary and plasma phytoestrogen levels and serum biochemical markers, bone specific-alkaline phosphatase (B-ALP) and urinary type I collagen cross Linked N-telopeptide (NTX), will be monitored every three months; BMD, measured by DEXA, and endometrial thickness, detected by transvaginal ultrasound, will be determined prior to and after the treatment. All patients will be treated and followed for at least 1 year. 

Specifically, several valuable results we expect to obtain: 1) a higher bone mineral density will be found in cases with
關鍵字：phytoestrogen , herbal regimen , postmenopausal osteoporosis